News

Filter

Current filters:

SandozFilgrastim

1 to 9 of 24 results

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

CHMP OKs Novartis

01-12-2008

At its late-November meeting, the European Medicines Agency's (EMEA) Committee for Medicinal Products…

AmgenFilgrastimNeupogenNovartisSandoz

1 to 9 of 24 results

Back to top